Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dual antiplatelet agent duration

Phase 3Small molecule

SSeoul National University Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2027

Post-ApprovalActive, not recruiting

Bleeding

NCT05631769

Clinical

Trials by Indication[1]

Bleeding1 trial

HOST - DAPT Duration According the Bleeding Risk

Active, not recruiting·SSeoul National University Hospital·Phase 4·NCT05631769·4,900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dual antiplatelet agent duration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dual antiplatelet agent duration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dual antiplatelet agent duration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSeoul National University Hospital

Related News